ClinicalTrials.gg
CompletedNCT03171818DINOSAURUpdated Nov 17, 2026

Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration

A Phase 2 interventional study of Darbepoetin Alfa and Saline in PAIS, Neonatal Stroke and Perinatal Stroke, sponsored by UMC Utrecht. Completed at 1 site in Netherlands. Open to participants aged Up to 7 Days. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by UMC Utrecht · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.
Updated Nov 17, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
Up to 7 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Stroke with a site in Netherlands — 23 open to participants now, 31 under way, 5 of them phase 3. Stroke · Netherlands.

Enrollment
71st of 91
80 · median 640
Started
2017
with 4 others
Phase 2
7 of 122
none open now
Registered
66th of 122
by date
Lead sponsor
6 of 122
UMC Utrecht

Among the 122 studies in Stroke with a site in Netherlands, this one is the 71st largest by enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2017, is one of 7 in phase 2, and was the 66th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

23 of the 122 studies in Stroke with a site in Netherlands are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: Up to 7 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Stroke with a site in Netherlands, or all of them as a file.
02

Study summary

The aim of the study is to perform a randomized double-blind placebo controlled prospective study in newborn infants with MRI confirmed Middle Cerebral Artery (MCA) Perinatal Arterial Ischemic Stroke (PAIS) with darbepoetin. It will be investigated whether intravenous administered darbepoetin can induce the formation of neuronal tissue and restore brain function in neonates who suffered from PAIS compared to placebo treated controls. The ultimate goal of this study is therefore to develop a therapy using erythropoiesis-stimulating agents (ESA) such as darbepoetin to reduce or even prevent lifelong consequences of PAIS-related brain injury in this group of term newborns.

03

Conditions studied

  • PAIS
  • Neonatal Stroke
  • Perinatal Stroke

Browse trials for

04

Who can participate

Ages eligible
Up to 7 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newborns ≥ 36+0 weeks of gestation, both male and female
  • MRI confirmed diagnosis of acute PAIS, in the MCA region with involvement of the cortical spinal tract (e.g. Posterior Limb of Internal Capsule [PLIC] or peduncles) within one week after birth
  • Written from custodial parent(s)

Exclusion criteria

Exclusion Criteria:

  • Moderate -severe Hypoxic-Ischemic Encephalopathy (HIE) with or without hypothermia therapy
  • Any proven or suspected major congenital anomaly, chromosomal disorder, metabolic disorder;
  • Presence of a serious infection of the central nervous system;
  • No realistic prospect of survival, (e.g. severe brain injury), at the discretion of the attending physician.
  • Infant for whom withdrawal of supportive care is being considered.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Darbepoetin

    Darbepoetin alfa (Aranesp, Amgen)

    Drug: Darbepoetin Alfa

  • Placebo comparator
    Placebo

    Saline

    Drug: Saline

Interventions

  • Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.

    Also known as: Aranesp

  • DrugSaline

    The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.

    Also known as: Sodium Chloride

06

What researchers measure

Primary outcomes

  1. Change in stroke tissue loss

    The primary objective is to determine whether there is a difference in the degree in stroke tissue loss between darbepoetin and placebo treatment, which will be measured by the change in lesion size between the time of onset of the insult and 6-8 weeks of age. The primary endpoint will be estimated using advanced volumetric magnetic resonance (MRI) techniques, performed within one week after clinical presentation and at 6-8 weeks of age.

    Time frame: 6-8 weeks of age

Secondary outcomes

  1. Reorganization of corticospinal connectivity

    To assess whether there are differences between darbepoetin and placebo treatment in Diffusion Tensor Imaging (DTI) parameters of selected regions of interest. DTI-MRI techniques are performed at 6-8 weeks of age.

    Time frame: 6-8 weeks of age

  2. Neurodevelopment

    To assess cognitive and motor development at 18 months of age using the Bayley Scales of Infants and Toddler Development (BSITD)-III scores compare them between groups (darbepoetin vs placebo).

    Time frame: 18 months of age

  3. Neurological assessment

    To assess neurological deficit and function using the Pediatric Stroke Outcome Measure (PSOM) and compare this score between groups (darbepoetin vs placebo). The PSOM is performed at 18 months of age.

    Time frame: 18 months of age

  4. Development of Cerebral Palsy

    Development of Unilateral Spastic Cerebral Palsy (USCP) using the Gross Motor Function Classification system (GMFCS) and compare this between groups (darbepoetin vs placebo).

    Time frame: 18 months of age

07

Study locations

1 site
  • Wilhelmina Childrens Hostpital/University Medical Center Utrecht
    Utrecht, Utrecht 3584 EA, Netherlands
08

References and documents

Publications

  • Benders MJ, van der Aa NE, Roks M, van Straaten HL, Isgum I, Viergever MA, Groenendaal F, de Vries LS, van Bel F. Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke. J Pediatr. 2014 Mar;164(3):481-6.e1-2. doi: 10.1016/j.jpeds.2013.10.084. Epub 2013 Dec 8. PubMed 24321539 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jun 2025, 95 months.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 95 months is above that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Dec 2024 → Jun 2025 and completion Jun 2025 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
May 31, 2017
StartActual
Jul 1, 2017
Primary completionActual
Jun 30, 2025was Dec 2024
CompletionActual
Nov 10, 2026was Jun 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 17, 2026
Sites
1 site added, 1 site removed
Show site
  • Wilhelmina Childrens Hostpital/University Medical Center Utrecht · Utrecht, Netherlands
Show 1 removed
  • Wilhelmina Childrens Hostpital/University Medical Center Utrecht · Utrecht, Netherlands
Nov 17, 2026
Primary completion
Dec 31, 2024→Jun 30, 2025 (actual)
Nov 17, 2026
Study completion
Jun 1, 2025→Nov 10, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Wilhelmina Childrens Hostpital/University Medical Center Utrecht · Utrecht, Netherlands
    Show 1 removed
    • Wilhelmina Childrens Hostpital/University Medical Center Utrecht · Utrecht, Netherlands
    Primary completion Dec 31, 2024→Jun 30, 2025 (now actual)
    Study completion Jun 1, 2025→Nov 10, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03171818
Lead sponsor
UMC Utrecht
Collaborators
Alberta Children's Hospital, The Hospital for Sick Children
Responsible party
dr. M.J.N.L. Benders (Principal Investigator UMC Utrecht, UMC Utrecht) — Principal investigator
First posted
May 31, 2017
Start date
Jul 1, 2017
Primary completion
Jun 30, 2025
Completion
Nov 10, 2026
Last update
Nov 17, 2026

Study contacts

Manon Benders, MD PhD
principal investigator · UMC Utrecht

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darbepoetin alfa

Start the discussion